Table 1.
Key Findings from different EZH2 models.
| Model | Genotype | Phenotype | Associated genes/Proteins | References |
|---|---|---|---|---|
| Infection | ||||
| L. monocytogenes-OVA | Ezh2fl/flCd4Cre | Reduced OVA-specific cells | (30) | |
| Ezh2fl/flCd4Cre-OT-I | Reduced Recovery; SLEC Skewed; Increased apoptosis | (30) | ||
| Ezh2fl/flGzmbCre | Reduced OVA-specific; no change in apoptosis; reduced cell cycling | (30) | ||
| LCMV | Ezh2fl/flGzmbCre | Reduced effector cells; increased viral burden; normal initial expansion; reduced TNFα production; CD127+CD62L+CD27+KLRG1Lo | Increased: FOXO1, Eomes, TCF-1, CD62L, CD27; Decreased: Tbet and KLRG1 | (28) |
| Ezh2fl/flCd4Cre-P14 | Reduced effector cells; reduced IFNγ and TNFα production; increased apoptotic cells; Increased CD25LoCD62LHi cells | (27) | ||
| Vaccinia virus | Ezh2fl/flCd4Cre-Pmel-I | Reduced frequency at acute time point; decreased frequency of IFNγ producing cells | (29) | |
| In vitro activation | Ezh2fl/flCd4Cre | Increased IFNγ, IL-2, Granzyme B; Increased apoptosis; Proliferation defects (CTV, BrdU) | Microarray: Ifng; Cdkn2a, Cdkn2b, Cdkn1c, | (30) |
| Ezh2fl/flGzmbCre | Increased cell cycling time | qRT-PCR: Cdkn2aV1/V2 | (30) | |
| Cancer | ||||
| Ezh2fl/flCd4Cre-Pmel-I | Reduced donor frequency/number; reduced TGI | (29) | ||
| Pmel-I transduced with phosphorylation insensitive EZH2 | Increased frequency/number; Increased number of IFNγ producing cells | RT-PCR: Increased: Id3; decreased: Prdm1, Eomes | (29) | |
| EZH2 inhibited activated hPBMC isolated T cells | Reduced polyfunctionality (IFNγ, TNFα, Granzyme B); increased apoptosis; decreased NOTCH signaling | Increased: Numb, Fbxw7; Decreased: Hes1, Hey1, Hey2 | (33) | |
Summation of the different conditional deletion and inhibition experiments targeting EZH2 or modulated EZH2 in T cells. Included in the table are mRNA and protein targets that were noted to be affected by modulating EZH2 activity.